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Abstract: Hypocretins or orexins (Hcrt/Orx) are hypothalamic neuropeptides that are synthesized by neurons located 
mainly in the perifornical area of the posterolateral hypothalamus. These hypothalamic neurons are the origin of an exten-
sive and divergent projection system innervating numerous structures of the central nervous system. In recent years it has 
become clear that these neuropeptides are involved in the regulation of many organic functions, such as feeding, ther-
moregulation and neuroendocrine and cardiovascular control, as well as in the control of the sleep-wakefulness cycle. In 
this respect, Hcrt/Orx activate two subtypes of G protein-coupled receptors (Hcrt/Orx1R and Hcrt/Orx2R) that show a 
partly segregated and prominent distribution in neural structures involved in sleep-wakefulness regulation. Wakefulness-
enhancing and/or sleep-suppressing actions of Hcrt/Orx have been reported in specific areas of the brainstem. Moreover, 
presently there are animal models of human narcolepsy consisting in modifications of Hcrt/Orx receptors or absence of 
these peptides. This strongly suggests that narcolepsy is the direct consequence of a hypofunction of the Hcrt/Orx system, 
which is most likely due to Hcrt/Orx neurons degeneration. 
The main focus of this review is to update and illustrate the available data on the actions of Hcrt/Orx neuropeptides with 
special interest in their participation in the control of the sleep-wakefulness cycle and the regulation of energy homeosta-
sis. Current pharmacological treatment of narcolepsy is also discussed. 
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food intake. 
INTRODUCTION 
  Hypocretins/orexins (Hcrt/Orx) are hypothalamic neu-
ropeptides that are synthesized by neurons located mainly in 
the perifornical area of the posterolateral hypothalamus. 
These hypothalamic neurons are the origin of an extensive 
and divergent projection system innervating numerous struc-
tures of the central nervous system (CNS). Hcrt/Orx neu-
ropeptides are involved in the regulation of many organic 
functions, such as feeding, thermoregulation and neuroendo-
crine and cardiovascular control, as well as in the control of 
the sleep-wakefulness cycle and expression of narcolepsy. 
Since the discovery of the Hcrt/Orx neuropeptides in 1998 
much information has been gathered about their actions in 
enhancing wakefulness and EEG activation. As well as in-
creasing wakefulness and food intake, administration of 
Hcrt/Orx neuropeptides also affects blood pressure, hormone 
secretion and locomotor activity (see for recent review [19]).  
HYPOCRETINS/OREXINS 
  Two independent research groups (the De Lecea and Sa-
kurai groups) simultaneously described the existence of two 
peptides synthesized by hypothalamic neurons [18,75]. De 
Lecea and collaborators observed that these peptides are ex-
pressed by neurons in the posterolateral hypothalamus that 
are very similar to the secretin-related peptides, so they   
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named them hypocretin-1 and hypocretin-2 (Hcrt-1 and Hcrt-
2; [18]). At the same time, Sakurai et al. [74,75] reported 
that central administration of these peptides increased feed-
ing behavior and called them orexin A (OrxA) and orexin B 
(OrxB). Hcrt/Orx neuropeptides act on two types of recep-
tors (ORX1R and ORX2R; also known as Hcrtr1R and 
Hcrtr2R; [75]), which are expressed throughout the CNS 
(Fig. 1).  
  Mammalian Hcrt/Orx1 is a 33 amino acid peptide with a 
molecular mass of roughly 3.5 kDa; it possesses an N-
terminal pyroglutamyl residue, a C-terminal amidation, and 
two intramolecular disulfide bridges, Cys6–Cys12 and Cys7-
Cys14. The amino acid sequence of Hcrt/Orx1 is remarkably 
well preserved in humans, cattle, rats, mice [75], and pigs 
[20]. 
  Mammalian Hcrt/Orx-2 is a 28 amino acid peptide with a 
molecular mass of about 2.9 kDa and a C-terminal amida-
tion. The structure of Hcrt/Orx-2 in solution has been deter-
mined by magnetic resonance imaging [47], and consists of 
two stable alpha-helices connected by a short linker. It shows 
46% (13/28) amino acid identity to Hcrt/Orx1. Rat and 
mouse Hcrt/Orx-2 are identical, and only one and two amino 
acid residues are changed in the porcine and human counter-
parts, respectively. Hcrt/Orx neuropeptides that have also 
been described in the frog Xenopus laevis has a high similar-
ity to the mammalian peptides [78]. The structure of 
Hcrt/Orx belongs to the incretin family of neuropeptides and 
has been strongly conserved during the evolution,  
  The Hcrt/Orx gene is located in chromosome 17q21-q24 
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tron, and encodes a 131 amino acid precursor peptide, pre-
pro-Hcrt/Orx. This precursor possesses an N-terminal 33 
residue secretory signal peptide, and is cleaved at sites of 
basic amino acid residue pairs by prohormone convertases to 
yield Hcrt/Orx1 and Hcrt/Orx2 [76]. The amino acid identity 
between human and rat prepro-Hcrt/Orx is 83%, with most 
substitutions occurring near the C-terminus. Given this struc-
ture, the existence of a third functional peptide derived from 
the C-terminal part of the precursor is unlikely. 
  The Hcrt/Orx neurons in the rat are restricted to the tu-
beral region of the hypothalamus, particularly the periforni-
cal region (PeF) and the lateral hypothalamic area (LHA) 
[18,75]. In the cat, Hcrt/Orx neurons are also concentrated in 
the same tuberal region, but extend widely to other hypotha-
lamic areas [89,106] (Fig. 2). Hcrt/Orxergic neurons are 
variable in size (diameter of cell body of 15–40 m) and 
shape (spherical, fusiform, multipolar) [16,17,63], and they 
have been assumed to number from 1,100 to 3,400 in the 
whole rat brain [34,69]. The human LHA has been estimated 
to hold about 50,000-80,000 Hcrt/Orx neurons [59]. Hcrt/ 
Orx axons are very heterogeneous in morphology; they can 
be either thick and very varicose or thin and slightly varicose 
[69]. Although Hcrt/Orx neurons are scarce, they have a pro-
fuse projection system to numerous brain regions involved in 
arousal and cortical activation and in sleep-wakefulness cy-
cle regulation. Among the main structures innervated by 
Hcrt/Orx neurons are the hypothalamus itself, the locus co-
eruleus (LC), the dorsal raphe nucleus (DR), and the cerebral 
cortex [50,53]. Hcrt/Orx neurons also innervate the brain-
stem reticular formation, including the REM sleep inducing 
region located in the ventral portion of the oral pontine re-
ticular nucleus (vRPO) [66] (Fig. 3).  
HYPOCRETIN/OREXIN RECEPTORS 
  Two Hcrt/Orx receptors (Hcrt/Orx1R and Hcrt/Orx2R) 
have been described. They show 64% amino acid identity 
and their structure is similar to most other peptidergic recep-
tors, to which they show an approximately 25–35% amino 
acid identity [75,76]. The amino acid homology between 
human and rat Hcrt/Orx receptors is 94% for Hcrt/Orx1R 
and 95% for Hcrt/Orx2R. The respective affinities (ex-
pressed as EC50, the concentration of ligand needed to elicit 
half-maximum receptor response) of Hcrt/Orx1 and 2 for 
Hcrt/Orx1R are 30 nM and 2500 nM. However, Hcrt/Orx1 
and 2 have affinities of 34 nM and 60 nM, respectively, for 
Hcrt/Orx2R [75]. This indicates that Hcrt/Orx2R is a nonse-
lective, high-affinity receptor for both Hcrt/Orx neuropep-
tides, whereas Hcrt/Orx1R is selective for Hcrt/Orx1 alone. 
Hcrt/Orx receptors are highly specific for Hcrt/Orx neurop-
eptides; neuropeptide Y, secretin, -melanocortin, and other 
neuropeptides do not activate Hcrt/Orx receptors [37,83] 
(Fig. 1).  
  Hcrt/Orx1R couple exclusively to the Gq/11 subclass of 
heterotrimeric G proteins, whereas Hcrt/Orx2R can couple to 
Fig. (1). Schematic depiction of hypocretin/orexin system. Hypocretin-1/Orexin A (Hcrt-1/OrxA) and hypocretin-2/Orexin B (Hcrt-2/OrxB) 
are derived from a common precursor peptide, pre-pro-hypocretin. After removal of the N-terminal secretory signal sequence, pre-pro-
hypocretin is cleaved at specific sites having basic amino acid residues to yield the two mature peptides. Hcrt-1/OrxA possesses two disulfide 
bridges while Hcrt-2/OxB is linear. The actions of hypocretins are mediated through interaction with two heterotrimeric G protein-coupled 
receptors (Hcrt/Orx1R and Hcrt/Orx2R), whose distribution in the central nervous system is regionally specific. Hcrt/Orx1R is more selective 
for Hcrt-1/OrxA, while Hcrt/Orx2R is equally specific for both peptides. Hcrt-1/OrxA is linked exclusively to excitatory G proteins of the Gq 
subclass, whereas Hcrt-2/OxB couples in vitro to excitatory Gq and/or inhibitory Gi/o. Signaling through Gq pathway results in increase of 
intracellular Ca
2+, most probably via activation of phospholipase C-b with subsequent triggering of the phosphatidylinositol cascade and 
activation of protein kinase C. The Ca
2+ influx likely induces depolarization. Signaling via inhibitory Gi/o pathway may occur through hy-
perpolarization due to K+ efflux (GIRK channel-mediated). Figure modified from [9]. 52    Current Neuropharmacology, 2009, Vol. 7, No. 1 Nuñez et al. 
Gq/11 or Gi/o proteins. Signaling through the Gq pathway 
results in nonselective cation channel activation leading to 
cellular depolarization, while Gi/o signaling activates in-
wardly-rectifying K
+ channels and leads to cellular hyperpo-
larization. Thus it is thought that Hcrt/Orx1R-mediated sig-
naling is excitatory through the Gq/11-mediated stimulation 
of phospholipase C, while Hcrt/Orx2R-mediated signaling 
can be either excitatory (when coupled to Gq/11) or inhibi-
tory through adenylate cyclase inhibition (when coupled to 
Gi/o), depending on the postsynaptic neurons [45].  
  The receptors are distinct gene products (hcrt-r1 and 
hcrt-r2) that show an apparently segregated form of mRNA 
expression in the rat. For example, hcrt-r1 mRNA is present 
in the LC, whereas hcrt-r2 mRNA is barely detectable [90]. 
Rat  Hcrt/Orx1R  and Hcrt/Orx2R  mRNAs are detected on 
postnatal day 1 and embryonic day 18, respectively, suggest-
ing the presence of Hcrt/Orx receptors at an early stage in 
hypothalamic development [93].  
  The mRNA distribution of Hcrt/Orx1R and of Hcrt/ 
Orx2R have been mapped in the complete adult rat brain. 
Hcrt/Orx1R mRNA was located in the prefrontal and infra-
limbic cortex, hippocampus, paraventricular thalamic nu-
cleus, ventromedial hypothalamic nucleus, DR, and LC. 
Hcrt/Orx2R  mRNA was detected in cerebral cortex, basal 
forebrain (BF) cholinergic nuclei, hippocampus, midline and 
intralaminar thalamus, raphe nuclei, and hypothalamic nuclei 
such as the tuberomammillary nucleus (TMN), dorsomedial, 
paraventricular, and ventral premammillary nuclei [30].  
  The distribution of Hcrt/Orx receptors is on the whole 
consistent with the location of the Hcrt/Orx axons and Hcrt/ 
OrxR mRNA-expressing neurons. Thus, the distribution pat-
terns of Hcrt/Orx1R and Hcrt/Orx2R coincide in some re-
gions but are distinct and complementary in some others. 
This suggests different physiological roles for each receptor 
subtype. Most of the noradrenergic LC neurons and cho-
linergic neurons in the pedunculopontine (PPT) and latero-
dorsal tegmental (LDT) nuclei express Hcrt-r1 mRNA and 
Hcrt/Orx1R. In contrast, serotonergic DR neurons and do-
paminergic ventral tegmental area (VTA) neurons express 
Hcrt-r1 mRNA and Hcrt/Orx1R and Hcrt-r2 mRNA and 
Hcrt/Orx2R in a more balanced manner. In the forebrain, the 
histaminergic TMN exclusively expresses Hcrt-r2 mRNA 
and Hcrt/Orx2R. 
Fig. (2). Distribution of Hcrt/Orx neurons in the cat hypothalamus. 
A: Microphotograph of a coronal section of cat hypothalamus 
showing the distribution of orexinergic neurons as result of the 
immunoreaction for anti-Orexin A antiserum. No counterstaining. 
B: High magnification of area squared in A. DHA. dorsal hypotha-
lamic area, LHA: lateral hypothalamic area, PeF: perifornical re-
gion, 3V: third ventricle. Calibration bars: A, 500 m, B, 100 m. 
Fig. (3). Sagittal scheme of the rat brain illustrating hypocretinergic influences on the cerebral cortex and wakefulness-promoting structures. 
Hypocretin/orexin (Hcrt/Orx) hypothalamic neurons send axons to both the cerebral cortex and neurochemically-specific neuronal groups 
projecting to the cortex, which are most involved in wakeulness maintenance and cortical activation. These groups are the noradrenergic 
locus coeruleus (LC), serotonergic dorsal raphe nucleus (RDo), cholinergic laterodorsal tegmental (LDT) and peduculopontine tegmental 
(PPT) nuclei, dopaminergic ventral tegmental area (VTA), histaminergic tuberomammilary nucleus (TMN) and cholinergic basal forebrain 
(BF) In the pontine tegmentum, Hcrt/Orx axons reach DOPT, where Hcrt/Orx enhance wakeulness, and also vRPO, where Hcrt/Orx suppress 
REM. Figure modified from [19]. Hypocretin/Orexin Neuropeptides  Current Neuropharmacology, 2009, Vol. 7, No. 1    53
 OX1R  mRNA has also been detected in structures other 
than CNS, such as the human adrenal zona fasciculata-
reticularis and adrenal medulla, which show very low levels 
of OX2R mRNA [55]. However, Jöhren and coworkers [40] 
demonstrated that the amount of OX1R mRNA in the pitui-
tary gland and of OX2R mRNAs in adrenal glands is higher 
in male than in female rats. These results suggest a sexually 
dimorphic role for Hcrt/Orx neuropeptides in peripheral or-
gans that is still poorly defined.  
ELECTROPHYSIOLOGICAL EFFECTS 
  Hcrt/Orx peptides have been shown to exert excitatory 
actions on noradrenergic LC neurons, histaminergic TMN 
neurons, and cholinergic mesopontine and BF neurons [11, 
13,21,22,32,38,39,99].  
  Whole-cell patch clamp recordings in slices from neurons 
of the rat LHA, superficial dorsal horn or laterodorsal teg-
mentum demonstrated an increase in the frequency of spon-
taneous and evoked excitatory or inhibitory postsynaptic 
potentials (EPSPs and IPSPs, respectively) when Hcrt/Orx 
was administered [13,31,92,93]. Also, cortical neurons in 
layer VI are activated by Hcrt/Orx through the closure of a 
potassium conductance [5].  
  Moreover, Hcrt/Orx, acting on Hcrt/OrxR2 receptors, has 
been reported to depolarize neurons and increase their excit-
ability either by activating an inward current [22,98] or by 
inhibiting an outward current [4]. The former occurs in TMN 
[22] and hippocampal [98] neurons and involves the activa-
tion of a Na
+/Ca
2+ exchange current. Moreover, activation of 
postsynaptic Hcrt/OrxR2 receptors also stimulates a Na
+/
Ca
2+ exchange current in arcuate Type-C GABAergic neu-
rons, thereby producing membrane depolarization and an 
increased firing rate. This effect is dependent on an increase 
in cytosolic Ca
2+ concentration, which is probably derived 
from intracellular stores [14]. 
  Van den Pol and colleagues [93]. have studied the second 
messenger system involved in Hcrt/Orx signaling. Both 
types of Hcrt/Orx increase Ca
2+ influx in medial and lateral 
hypothalamic neurons, as measured by fura-2 imaging, in 
about one third of hypothalamic neurons, probably by open-
ing a plasmatic membrane Ca
2+ channel. Hcrt/Orx responses 
are completely blocked by the PKC-specific inhibitor bisin-
dolylmaleide, suggesting that Hcrt/Orx may work via Gq-
activated PKC, resulting in Ca
2+ channel phosphorylation 
that has been reported to increase Ca
2+  conductance [52]. 
More recent studies have shown that Hcrt/Orx may be linked 
to the adenyl cyclase pathway [55], probably via an interac-
tion between Hcrt/Orx-2 neuropeptides and Gi proteins 
[41,71].  
HYPOCRETINS/OREXINS AND ENERGY HOMEO-
STASIS 
  The hypothalamus has long been implicated in the regu-
lation of food intake, body mass, body temperature and en-
ergy balance. The LHA would be responsible for the initia-
tion of food intake, while the basomedial hypothalamic nu-
clei are associated with the cessation of food intake [7,8]. 
Moreover, Hcrt/Orx1 also increases food intake in satiated 
rats when infused intracerebroventricularly [102,103]. Fur-
thermore, intraperitoneal injection of the selective Hcrt/ 
Orx1R antagonist (SB-334867-A) significantly reduced food 
intake and increased resting behavior in rats [35,73]. 
  The molecular bases of food intake control are the appe-
tite-stimulating (orexigenic) neuropeptides, such as melanin-
concentrating hormone (MCH) [94], galanin [56], and dynor-
phin [95], which have been reported in the LHA neurons. In 
addition to food intake, Hcrt/Orx neuropeptides have also 
been implicated in the regulation of drinking behavior [46].  
  The Hcrt/Orx system is activated in situations in which 
little food is available, since 48-h fasting increases prepro-
Hcrt/Orx mRNA levels in rats [75]. Insulin-induced hypogly-
cemia activates of Hcrt/Orx neurons, as determined by im-
munohistochemical staining against Fos protein [61]. Fasting 
in humans (ten nonobese females) results in an increase in 
plasma Hcrt/Orx1 paralleled by a reduction in plasma leptin 
levels [43]. 
  Consequently, data indicate that Hcrt/Orx neurons are 
involved in an appetite regulatory circuit that includes the 
circulating hormone leptin, which is secreted by adipocytes 
according to total body adipose mass. The actions of leptin 
are partly mediated by the LHA, where it decreases the firing 
rate of both glucose-sensitive and glucose-insensitive neu-
rons. In contrast, Hcrt/Orx1 increases the activity of glucose-
sensitive neurons [79]. Patch-clamp measurements in iso-
lated Hcrt/Orx neurons indicate that leptin, as well as high 
extracellular glucose levels, can directly decrease the neu-
ronal firing rate and intracellular Ca
2+ concentrations [62]. 
Exogenously administered Hcrt/Orx neuropeptides them-
selves also reduce the firing rate of these neurons. It is there-
fore likely that some of the leptin-sensitive and glucose-
sensitive neurons in the LHA described by Shiraishi and 
coworkers [79] are in fact Hcrt/Orx neurons, and that these 
cells express inhibitory Hcrt/Orx autoreceptors.  
  It has also been pointed out that Hcrt/Orx can play a role 
in the control of body temperature. Anatomical evidences 
have demonstrated polysynaptic connections to thermogenic 
sites, such as the brown adipose tissue, from Hcrt/Orx neu-
rons in the lateral hypothalamus suggesting the possibility 
that these neurons represent the anatomical substrate for two 
independent components for energy homeostasis, feeding 
and thermogenesis [67,68]. On the other hand, intracere-
broventricular injections of Hcrt1/OrxA in mice neither in-
creased the metabolic rate nor modified the body tempera-
ture, while the receptor antagonist SB-334867-A injected 
intraperitoneally acts as a thermogenic agent producing a 
significant increase in energy expenditure [36,51]. These two 
different effects can be due to that the antagonist has a direct 
effect on peripheral thermogenic sites although orexin re-
lease at these sites has not been demonstrated [36]. Since a 
close relationship between body temperature cycle and sleep-
wakefulness cycle has been widely demonstrated (se for re-
view [29]), it could be possible that Hcrt/Orx participate in 
the mediation of this relationship. 
HYPOCRETINS/OREXINS AND SLEEP-WAKEFUL-
NESS CYCLE 
  The stages that characterize the sleep-wakefulness cycle 
are distinguished by different electrophysiological patterns in 54    Current Neuropharmacology, 2009, Vol. 7, No. 1 Nuñez et al. 
the electroencephalogram (EEG) and in other bioelectrical 
signals. Wakefulness is characterized by low-amplitude and 
fast EEG, while slow wave sleep (non-REM sleep) by high 
amplitude and slow EEG waves. This pattern develops fur-
ther into high-frequency EEG waves that define the stage of 
REM sleep. Switching among these states is controlled in 
part by the activities of hypothalamic neurons and several 
areas located in the brainstem. 
  The Hcrt/Orx neuropeptides have been implicated in the 
control of the sleep-wakefulness cycle. Since the Hcrt/Orx 
neuropeptides were discovered, much data has been col-
lected about their ability to enhance wakefulness and cortical 
EEGactivation.Intracerebroventricularinfusion of Hcrt/Orx1 
produces an increase in wakefulness at the expenses of non-
REM sleep and a remarkable decrease in REM sleep [32]. 
Moreover, most of the neurons within the PeF area, includ-
ing the Hcrt/Orx neurons, increase their firing rate during 
alert wakefulness and decrease their activity during slow 
wave sleep and REM sleep in absence of twitches [2,44, 
48,58]. However, Torterolo and coworkers [87] reported that 
significant c-fos expression in Hcrt/Orx-containing cells was 
detected during both active wakefulness and the carbachol 
induced REM sleep-like state. They found that 79% of the 
total number of hypocretinergic neurons detected were active 
during active wakefulness, approximately 34% of them were 
active during carbachol induced REM sleep, and only 2% 
were active during quiet wakefulness. Moreover, Kiyash-
chenko and coworkers [42] described maximal Hcrt-1 re-
lease in the hypothalamus and basal forebrain during both 
REM sleep and active wakefulness and minimal release dur-
ing slow wave sleep. Thus, it is possible that the level of 
Hcrt/Orx1 may dependent on the intensity of motor system 
activation (see below) since central motor systems reach 
discharge levels equal to or greater than those of active wak-
ing during REM sleep and have minimal discharge during 
slow wave sleep [80,81]. 
  The implication of Hcrt/Orx in sleep-wakefulness control 
is certainly the consequence of the existence of strong ana-
tomical connections from Hcrt/Ox neurons to the major areas 
responsible for the generation of the different sleep-wake-
fulness states [24,25,63,69,107] (Fig. 3). Hcrt/Orx neuropep-
tides excite DR, LC, TMN, LDT and PPT nuclei, as well as 
BF cholinergic neurons, by activating postsynaptic receptors 
in these neurons [11,21,23,32,39]. These “wake-active” nu-
clei are implicated in maintaining wakefulness. Accordingly, 
Hcrt/Ox neuropeptides promote wakefulness when adminis-
tered in these regions [11,24,85,99]. Monoaminergic neurons 
in these nuclei are most active during wakefulness, slow 
down during non-REM sleep, and nearly cease firing during 
REM sleep, probably due to a decrease of the excitatory 
Hcrt/Orx inputs. 
  In relation with the control of REM sleep generation, 
Hcrt/Orx projections and receptors have been identified in 
cholinoceptive areas of the pontine reticular formation in-
volved in REM generation and control of REM-polygraphic 
signs [30,53,97,107]. Furthermore, Hcrt/Orx enhances ace-
tylcholine and GABA release in these areas [6,96]. However, 
altering Hcrt/Orx neurotransmission in the pontine tegmen-
tum has led to conflicting results in behaving animals. Some 
studies have reported a facilitation of REM sleep after 
Hcrt/Orx increase in the pontine tegmentum [99-101] but 
others groups have reported a Hcrt/Orx inhibitory action on 
REM sleep [10,84].  
  These discrepancies may be the result of the different 
cellular actions produced by Hcrt/Orx at the level of the dor-
sal oral pontine tegmentum (DOPT) and in the ventral part of 
the oral pontine reticular nucleus (vRPO), which is impli-
cated in REM sleep generation [27,28,60,72], Hcrt/Orx in 
DOPT was recently found to produce excitatory electro-
physiological responses in both cholinergic and noradrener-
gic cells [12]. In contrast, we have demonstrated that ionto-
phoretic application of Hcrt/Orx through a barrel micropi-
pette in the vRPO induces inhibition by activation of 
GABAA receptors because is blocked by application of the 
GABAA antagonist bicuculline [66]. There is a specific 
Hcrt/Orx projection from the PeF area to the vRPO [66]. 
Therefore, the PeF area might control REM generation 
through a hypocretinergic projection that would activate 
GABAergic mechanisms. 
  Recent experiments in our laboratory have shown that 
Hcrt/Orx neuropeptides have a wake-promoting and sleep-
suppressing actions when acting in the DOPT and a direct 
and exclusive inhibition of REM sleep when acting in the 
vRPO [60] (Fig. 4 ). Also a defacilitating action on REM 
sleep could be secondarily produced by the wake-promoting 
and sleep-suppressing actions of Hcrt/Orx in other pontine 
areas such as the principal LC and LDT nuclei [11,99]. The 
loss of Hcrt/Orx signaling in narcolepsy disease would im-
pair these actions and could remove the defacilitat-
ing/inhibiting actions on REM generation of the Hcrt/Orx 
signal in these pontine regions during wakefulness; conse-
quently, patients would fall directly into REM while still in a 
wakefulness period (see below). 
  Hcrt/Orx neurons may be also involved in motor activity. 
Hcrt/Orx cells discharge during active waking, when pos-
tural muscle tone is high in association with movements, 
decrease discharge during quiet waking in the absence of 
movements, and virtually cease firing during sleep, when 
postural muscle tone is low or absent [2, 48, 58]. However, 
Hcrt/Orx-containing neurons are also activated during car-
bachol-induced REM sleep with muscular twitches [88]. The 
relationship between hypocretinergic system activation and 
motor activation is reinforced by decrease in Hcr/Orx1 levels 
in CSF of rats after long-term immobilization and its in-
creased levels after short-term forced swimming [54,86]. The 
peptide concentration in dialysates from the hypothalamus 
was significantly higher during active waking than during 
slow-wave sleep [42]. Moreover, systemic, intracerebroven-
tricular, and intraparenchymal injection of Hcrt/Orx in-
creases motor activity [42,86].  
  In agreement with a putative role for the hypocretinergic 
system in motor functions, Hcrt/Orx terminals have been 
found in the ventral horn where motoneuron cell bodies are 
located [91]. In addition, application of hypocretin depolar-
izes lumbar motoneurons by means of presynaptic and post-
synaptic mechanisms that result in the facilitation of their 
discharges [104]. These authors propose that this action of 
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lation of motor activity in situations that involve certain hy-
pothalamus-driven behaviors. 
  Another question of interest is the mechanism for cir-
cadian regulation of Hcrt/Orx neurons. As mentioned above, 
Hcrt/Orx neuron activity follows a circadian rhythm as dem-
onstrated by both Fos-immunostaining [26] and Hcrt/Orx 
peptide levels measured in the rat cisterna magna [105]. 
Hcrt/Orx neurons in rats and humans were recently shown to 
be directly innervated by neurons of the suprachiasmatic 
nucleus, a structure that is responsible for regulation of cir-
cadian processes [1]. Hcrt/Orx neurons may therefore be a 
relay station for circadian sleep/wake control by the su-
prachiasmatic nucleus. 
HYPOCRETINS/OREXINS AND NARCOLEPSY 
  Idiopathic narcolepsy is more frequent than commonly 
thought, having approximate prevalences 1 in 1,000–2,000 in 
the United States [82] and 1 in 600 in Japan [57]. This neuro-
logical disorder is characterized by a primary disturbance in 
sleep-wakefulness organization. The onset of narcolepsy 
most often occurs during adolescence and the symptoms 
gradually reach a certain severity within several years, after 
which patient condition neither worsens nor improves.  
  Narcoleptic patients suffer from severe daytime hyper-
somnolence, combined with night time insomnia and sleep 
fragmentation, which produces a constant feeling of tired-
ness in these subjects. In healthy human subjects the latency 
Fig. (4). Mean time spent ± SEM of the sleep-wakefulness cycle states by animals with Hcrt-1 microinjections in either the dorsal oral pon-
tine tegmentum (DOPT) or the ventral oral pontine tegmentum (vRPO) in each of the first 3 h of polygraphic recordings in baseline and after 
Hcrt-1 1000 mM dose experiments. *Statistically significant difference in comparison with baseline. Post hoc analyses (Fisher's test, P < 
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for REM sleep after the onset of non-REM sleep is around 
90–100 min. In contrast, in narcoleptic patients, REM sleep 
latency is frequently shortened to less than 15 min, some-
times being so short that even direct transitions from wake-
fulness to REM sleep occur, something which can under-
standably cause embarrassing and even dangerous situations. 
This “sleep-onset REM period” is regarded as the diagnostic 
indication for narcolepsy. 
  However, the most striking feature of the disease is cata-
plexy, a sudden bilateral loss of skeletal muscle tone during 
wakefulness; it is most often triggered by a strong positive 
swing of emotion such as laughter (a trigger in 80% of cases) 
[3]. Cataplectic attacks normally last from a few seconds to a 
few minutes and range in severity from slurred speech, head 
dropping, and knee jerking to complete collapse to the floor 
despite maintained consciousness [3]. All these clinical 
symptoms suggest that narcolepsy is a dysfunction of vigi-
lance state boundary control, in which the fundamental 
pathophysiology involves an abnormal and premature intru-
sion of REM sleep into the state of wakefulness. 
  Current pharmacological treatment of narcolepsy is based 
on two approaches, although a host of different therapies are 
in use [64]. Excessive daytime sleepiness is currently treated 
with either amphetamine-like stimulants or the stimulant 
modafinil, both of which increase the catecholaminergic 
tone. Amphetamines increase catecholamine release and also 
reduce catecholamine uptake by inhibiting monoamine 
transporters, however they have considerable sympathetic 
side effects. Modafinil is structurally unrelated to ampheta-
mines and presently constitutes a better first-line treatment 
for excessive daytime sleepiness and sleep attacks. Although 
the mechanism of action of modafinil is not yet fully under-
stood, it is thought to consist mainly in inhibition of the do-
pamine transporter. Interestingly, administration of modafinil 
or amphetamine-like stimulants to mice increases Fos-
expression in Hcrt/Orx neurons of the hypothalamus [15] or 
of the TMN [77]. Since both amphetamines and modafinil 
also enhance wakefulness in Hcrt/Orx-deficient narcoleptic 
subjects, it appears that their sites of action are largely inde-
pendent of the Hcrt/Orx system, and their advantageous ac-
tions in narcolepsy would be purely symptomatic. 
  Despite promotion of wakefulness, these stimulants do 
not improve other REM sleep-related narcolepsy symptoms. 
For the treatment of cataplexy, tricyclic antidepressants such 
as imipramine, protryptiline, and clomipramine have been 
commonly used and are still widely prescribed. These drugs 
act by blocking reuptake of noradrenaline and serotonin, and 
they have considerable anticholinergic side effects [9]. The 
newer antidepressants, such as fluoxetine, are clinically less 
effective, although they have significantly less side effects. 
Sodium oxybate is, at present, the first-line treatment for 
cataplexy. It is the sodium salt of the natural neurotransmit-
ter gamma-hydroxybutyric acid, and it binds to its own re-
ceptors at physiologic concentrations; however, when used at 
higher pharmacological concentrations, sodium oxybate acts 
mainly through GABAB receptors. 
  Animal models of human narcolepsy consist in modifica-
tions of Hcrt/Orx receptors [49] or absence of these peptides 
[15]. Hcrt/Orx knockout mice display a severe narcolepsy-
like phenotype [33]. This is also evident in double receptor 
knockout (Hcrt/Orx1R- and Hcrt/Orx2R-null) mice. In con-
trast, knockout mice for either Hcrt/Orx1R or Hcrt/Orx2R 
show phenotypes that is somewhat different. Hcrt/Orx1R 
deficient mice only exhibit slightly increased sleep fragmen-
tation and lack evident behavioral abnormalities. Hcrt/Orx2R 
knockout mice also show a mild narcoleptic phenotype, in 
which fragmentation of sleep is present but abnormalities of 
REM sleep, such as direct transitions from wakefulness to 
REM sleep, are either absent or much less frequent than in 
double-null animals. These data suggest that Hcrt/Orx2R is 
critical for normal regulation of wakefulness/non-REM tran-
sitions, whereas the intense deregulation of REM sleep con-
trol present in the narcoleptic syndrome relies on signaling 
disruption through both Hcrt/Orx1R and Hcrt/Orx2R.  
  Nowadays it is assumed that narcolepsy is the direct con-
sequence of Hcrt/Orx neuron degeneration, and therefore 
indicates widespread Hcrt/Orx hypofunction. There are dif-
ferent reasons to link Hcrt/Orx and human narcolepsy. Nar-
coleptic patients have fewer Hcrt/Orx neurons in the postero-
lateral hypothalamus than control subjects [70,86], and their 
cerebrospinal fluid shows lower or untraceable Hcrt/Orx 
levels [65]. Moreover, gliosis has been reported in the peri-
fornical area in some narcoleptic patients [70,86]. All these 
observations, together with the well known association be-
tween narcolepsy and specific antigens of the major histo-
compatibility system (HLA), suggest that an autoimmune 
process might be the triggering factor initiating hypothalamic 
Hcrt/Orx neuron degeneration in narcolepsy. The astrocytic 
marker GFAP (glial fibrillary acidic protein) for gliosis 
seems to be present in a few narcoleptic patients, and might 
be found in more since the analyzed tissue had been stored 
for a long time and could have lost immunoreactivity [86]. 
Although Hcrt/Orx neuronal degeneration is the most ac-
cepted hypothesis for human narcolepsy, other possible 
causes, including defects in the synthesis of Hcrt/Orx or their 
receptors cannot be rejected. Hereditary canine narcolepsy 
caused by a mutation in hcrt2R/ox2R [49] or rodent models 
of narcolepsy due to deletion of the Hcrt/Orx gene [15] have 
been well documented.  
  At the present time, Hcrt/Orx neuropeptides are consid-
ered to be neuromodulators that enhance the waking state 
through increasing the activity of several neuronal popula-
tions; they also inhibit REM sleep by acting on the vRPO 
(see above). Impairment of the Hcrt/Orx neuron projection 
system or actions would provoke, on one hand, hypoactivity 
of the ascending activating systems, and, on the other hand, 
disinhibition of the vRPO and REM sleep triggering. This 
hypothesis could explain the great number of transitions be-
tween wakefulness and sleep, REM sleep fragmentation and 
hypersomnia present in narcoleptic patients. 
CONCLUSIONS 
  The Hcrt/Orx neuropeptide system has proven to be a 
novel mechanism by which the brain regulates arousal and 
sleep/wake states. Also, these neuropeptides contribute to 
regulation of energy homeostasis. The link between narco-
lepsy and Hcrt/Orx deficiency in animals and humans has 
provided a better understanding of sleep-wakefulness regula-
tion and the cause of narcolepsy. Different studies clearly Hypocretin/Orexin Neuropeptides  Current Neuropharmacology, 2009, Vol. 7, No. 1    57
demonstrate that Hcrt/Orx neuropeptides favored the activity 
of neurons implicated in wakefulness generation while at the 
same time, they inhibit neurons involved in REM sleep gen-
eration. 
  Discovery of the pathogenic mechanisms that underlie 
the loss of Hcrt/Orx neurons in humans will constitute a cru-
cial boost for narcolepsy research in the future. That infor-
mation is essential for the prevention and treatment of this 
disease. 
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